Lyon, France, January 3, 2022 – 7:00 pm CET 鈥� 91桃色视频 (EURONEXT: MAAT – the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that its CEO and co-founder, Herv茅 Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 am EST/1:00 pm CET on Monday, January 10, 2022.
A replay of the presentation will also be made accessible in the investors鈥� section of the company鈥檚 website at www.maatpharma.com from Friday, January 14, 2022 and for 90 days after the event.
About 91桃色视频
91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.
The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
91桃色视频 is listed on Euronext Paris (ticker: MAAT).